PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 11, 2026Case Reports in Oncological Medicine0 citationsOpen Access

Acral Lentiginous Melanoma With NRAS Mutation and Ocular Surface Toxicity Following Immunotherapy and Investigational KRASG12C Inhibitor: Case Report

View Full Paper
EHElisah M. HuynhAGAndrew GregoryPCPeter Y. Chang

Key Points

  • To address ocular surface toxicity resulting from systemic therapies in a case of acral lentiginous melanoma with NRAS mutation.
  • Clinical trial enrollment for anti-RAS agent RMC-6236
  • Evaluation of ocular surface health
  • Monitoring corneal defects and their progression
  • Patient developed chronic bilateral corneal epithelial defects
  • Corneal thinning observed as a side effect of targeted therapy
  • Findings emphasize the significance of multidisciplinary management in cancer treatment

Abstract

We report the case of a patient with metastatic foot melanoma enrolled in a clinical trial of the anti‐RAS agent RMC‐6236 who developed chronic bilateral corneal epithelial defects and thinning, likely secondary to the systemic effects of targeted therapy. This case highlights the ocular surface toxicity associated with systemic anticancer therapies affecting rapidly dividing cells and the overall importance of multidisciplinary medical management of these systemic therapeutics.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Huynh et al. (2026) studied this question.

synapsesocial.com/papers/69d9e5ec78050d08c1b76302https://doi.org/10.1155/crom/7529882
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ocular Effects of MEK Inhibitor Therapy: Literature Review, Clinical Presentation, and Best Practices for Mitigation2024 · 36 citations
  2. 2New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)2008 · 30,018 citations
  3. 3Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC).2025 · 51 citations
  4. 4Prognostic factors and survival in acral lentiginous melanoma2017 · 62 citations
  5. 5OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS2019 · 118 citations